The vaccine candidate uses the Adenovirus-35 vector technology and expresses HIV-1 antigens. Building on Transgene’s viral vectors manufacturing processes and long experience in the field, two vaccine batches and related pharmaceutical intermediates will be produced in Transgene’s manufacturing facility located near Strasbourg, France. Under the terms of this 18-month contract, financial details are to remain confidential.
Transgene and IAVI have worked together on two additional projects over the past three years including the manufacturing of several MVA (modified vaccinia ankara) constructs including SIV (simian immunodeficiency virus) genes and a study on the characterization of another vaccine candidate.
Philippe Archinard, CEO of Transgene said of the contract: “It validates the quality of our manufacturing technology platform and competencies and will contribute to building our revenue stream over 2006 and 2007.”